NCT00337701 - BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection | Biotech Hunter

Enrollment

326

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

January 31, 2007

Study Completion Date

January 31, 2007

Conditions

HIV Infections

Interventions

DRUG

enfuvirtide [Fuzeon]

90mg sc bid by Biojector 2000 NFID for 8 weeks

DRUG

enfuvirtide [Fuzeon]

90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.

Trial Locations (44)

10011

New York

10016

New York

14604

Rochester

19107

Philadelphia

20910

Silver Spring

21201

Baltimore

23666

Hampton

27103

Winston-Salem

30033

Decatur

30318

Atlanta

32803

Orlando

33169

North Miami Beach

33316

Fort Lauderdale

33317

Plantation

33614

Tampa

33901

Fort Myers

34952

Port Saint Lucie

60657

Chicago

63117

St Louis

63139

St Louis

76104

Fort Worth

77027

Houston

77098

Houston

77555

Galveston

80220

Denver

83704

Boise

85006

Phoenix

85012

Phoenix

90036

Los Angeles

90813

Long Beach

92262

Palm Springs

92708

Fountain Valley

94115

San Francisco

94545

Hayward

95051

Santa Clara

99204

Spokane

35294-2050

Birmingham

02215-3318

Boston

48072-1550

Berkley

08244

Somers Point

08043

Voorhees Township

97209-2534

Portland

00717-1563

Ponce

00909

Santurce